Approximately 1.0-1.5% of the genome is transcriptionally regulated by hypoxia, and hypoxia-inducible factor (HIF)-1α is the transcription factor modulating many of these genes. Cancer cells are able to survive hypoxic environments and hypoxia itself can activate adaptive cellular responses that contribute to tumor progression. Many HIF-1α-mediated biological effects are beneficial for tumor progression, including metabolic shift toward glycolysis, inhibition of fatty acid β-oxidation, production of cellular reac-reactive oxygen species and altering expression of tumor suppressor genes. HIF-1 promotes selective mitochondrial autophagy, resisand altering expression of tumor suppressor genes. HIF-1 promotes selective mitochondrial autophagy, resistance to T cell mediated lysis of cancer cells, induction of pluripotent cancer stem cells, epithelial-mesenchymal and epithelialmesenchymal-endothelial transitions beneficial for tumor growth and progression, loss of E-cadherin. HIF-1 also induces production of signal molecules and cytokines by carcinoma-associated fibroblasts and upregulation of certain microRNAs important for cancer progression. This minireview focuses on the HIF-1 promoting role in tumor initiation and progression and HIF-1 targeting. HIF-1 pathway downregulation seems to be promising in future cancer treatment. Key Words: adaptive cellular response, cancer stemness, hypoxia, hypoxia-inducible factor 1, tumor progression.
Hypoxia-inducible factor �HIF�-� plays an essential role in cellular and systemic oxygen �omeostasis [�] . Approximately �.���.5% of t�e genome is transcriptionally regulated by �ypoxia� and HIF-�α is t�e transcription factor modulating many of t�ese genes [�] . Under normoxic conditions� HIF-�α �as a �alf-life in cytoplasm of < 5 min� but �ypoxic conditions stabilize HIF-�α� w�ic� escapes degradation and translocates to t�e nucleus [�] . In t�e nucleus� dimerisation of HIF-�α wit� HIF-�β under �ypoxic conditions results in t�e formation of t�e HIF-� transcription factor� w�ic� binds to �ypoxia response elements and activates t�e transcription of O � -dependent genes [�] . Insufficient oxygen supply produces stressful environments for normal cells and can promote cell deat� in �ypoxic regions by eit�er apoptosis or necrosis [�] .
Poorly vascularized and perfused tumor microareas in many aggressive cancers �ave limited access not only to oxygen but also to glucose. Core regions are also associated wit� acidic pH since t�ese tumor cells c�ange t�eir metabolism towards increased glycolysis� resulting in increased lactic acid production. Abnormal vascularization of solid tumors results in t�e development of microenvironments deprived of oxygen and nutrients t�at �arbour slowly growing and metabolically stressed cells. Suc� cells display en�anced resistance to standard c�emot�erapeutic agents and repopulate tumors after t�erapy [4] .
Cancer cells are able to survive �ypoxic environments and �ypoxia itself can activate adaptive cellular responses t�at contribute to tumor progression [5] . �any HIF-�α-mediated biological effects are ben eficial for tumor progression� including s�ifting metabolism toward glycolysis� induction of angiogenesis� regulation of apoptosis� induction of migration to escape �ostile �ypoxic environments� and t�erapy resistance [5� �].
Induction of HIF-�α �as two effects in tumor cells: i. HIF-�α triggers t�e p�osp�orylation of Src w�ic� subsequently p�osp�orylates t�e tyrosine residue Y7�5 of STAT� �signal transducer and activasignal transducer and activator of transcription ��; ii. HIF-�α activates autop�agy by a mec�anism implicating t�e increased expression of BCL�/adenovirus E�B �� kDa protein-interacting protein � �BNIP��/BNIP�-like �BNIP�L� and t�e dis-BNIP�-like �BNIP�L� and t�e dis-�BNIP�L� and t�e dissociation of t�e beclin �-BCL� �B cell lymp�oma �� complex [7] .
By upregulating t�e expression of BNIP� and BNIP�L� HIF-� promotes selective mitoc�ondrial autop�agy [7] . Autop�agy is typically a stress adaptation mec�anism in response to a variety of stress stimuli including starvation� �ypoxia� endoplasmic reticulum stress� and oxidative stress t�at trigger a pro-survival pat�way avoiding cell deat�. In cancer t�erapy� autop�agy is activated as an adaptive response to promote cell survival. Autop�agy ensures cell metabolism� supplies tumor cell survival and prevents cancer cells from accumulating dysfunctions [�] . During cancer progression� autop�agy can be induced by different stresses� particularly �ypoxia� nutrient deprivation� or extracellular matrix detac�ment. Recent evidence �as demonstrated t�at tumor cells can escape natural killer �NK�-mediated immune surveillance by activating autop�agy under �ypoxia [7] .
An interesting recent report �as proved t�at lymp�oid effectors not only provide lytic signals but also promote autop�agy in t�e remaining target cells� a process called cell-mediated autop�agy [7] . T�us� cell-mediated autop�agy �as been reported in difSubmitted: November 03, 2015.
Correspondence: E-mail: jasna.ajdukovic@gmail.com Abbreviations used: ALL -acute lymphoblastic leukemia; BNIP3 -BCL2/adenovirus E1B 19 kDa interacting protein 3; BNIP3L -BNIP3-like; CAF -carcinoma-associated fibroblast; CSC -cancer stem cell; CTGF -connective tissue growth factor; EMT -epithelialmesenchymal transition; FA� -fatty acid �-o�idation; GPE� -G protransition; FA� -fatty acid �-o�idation; GPE� -G protransition; FA� -fatty acid �-o�idation; GPE� -G pro-; FA� -fatty acid �-o�idation; GPE� -G profatty acid �-o�idation; GPE� -G proacid �-o�idation; GPE� -G proacid �-o�idation; GPE� -G pro-�-o�idation; GPE� -G pro-�-o�idation; GPE� -G pro--o�idation; GPE� -G proo�idation; GPE� -G pro-; GPE� -G protein-coupled estrogen receptor; HIF-1 -hypo�ia-inducible factor 1; LCAD -long-chain acyl-CoA dehydrogenase; MCAD -medium-chain acyl-CoA dehydrogenase; mi� -micro�NA; NK -natural killer; ��S -reactive o�ygen species; TAZ -transcriptional co-activator with PDZ-binding motif; VEGF -vascular endothelial growth factor.
Exp Oncol ���� ��� �� ���� MINIREVIEW ferent �uman epit�elial tumors after interaction wit� immune cells at a �ig� ratio of effectors to targets. Importantly� it �as been s�own t�at cell-mediated autop�agy not only acts as a mec�anism of resistance to immune cell-mediated lysis but also limits t�e cytotoxic activity of stress factors suc� as γ-radiation [7] . BNIP�L and BNIP� also play roles in t�e mediation of mitop�agy allowing t�e cells to get rid of dysfunctional mitoc�ondria and promote virus-specific NK cell survival during t�e contraction p�ase of t�e response to murine cytomegalovirus. It �as implications for t�e development of effective antiviral and anticancer treatments� as well as vaccination strategies targeting t�e autop�agy pat�way in NK cells [�] .
In breast cancer in response to reduced O � availability� HIF-� mediates t�e transcriptional activation of genes encoding proteins t�at are required for many important steps in progression� suc� as angiogenesis� cancer stem cell �CSC� maintenance� cell motility� epit�elial-mesenc�ymal transition �E�T�� extracellular matrix remodeling� metabolic reprogramming� metastasis� and resistance to t�erapy [��] . HIF-� binds directly to gene encoding t�e transcriptional coactivator wit� PDZ-binding motif �TAZ�� an effector of Hippo signaling. TAZ interacts wit� DNA binding proteins to activate transcription of target genes� suc� as CTGF �encoding connective tissue growt� factor�� w�ic� promote E�T and t�e breast cancer stem-cell p�enotype bidirectional functional interactions between HIF-�α and TAZ t�at synergistically drive t�e expression of downstream target genes in �ypoxic breast cancer cells [��] .
Carcinoma-associated fibroblasts �CAFs� play a pivotal role in cancer progression by contributing to invasion� metastasis and angiogenesis [��] . Hypoxia upregulates HIF-�α� G protein-coupled estrogen receptor �GPER� and smoot� muscle actin α expression in CAFs� and induces t�e secretion of interleukin-�� vascular endot�elial growt� factor �VEGF�� and CTGF in CAFs [��] . As a biological counterpart of t�ese findings� conditioned medium from �ypoxic CAFs promotes tube formation in �uman umbilical vein endot�elial cells in a HIF-�α/GPER dependent manner. T�e functional cooperation between HIF-�α and GPER in CAFs was also evidenced in t�e �ypoxia-induced cell migration� w�ic� involves a furt�er target of t�e HIF-�α/GPER signaling like CTGF [��] .
HIFs may promote a CSC state� w�ereas t�e loss of HIFs induces t�e production of cellular reactive oxygen species �ROS� and activation of p5� and In T�e recent discovery t�at a subset of cellular microRNAs �miRs� are upregulated during �ypoxia� w�ere t�ey function to promote tumor development� �ig�lig�ts t�e importance of �ypoxia-induced miRs as targets for continued investigation. Under �ypoxic conditions� miR-��� becomes �ig�ly upregulated in response to HIFs. HIF-�α drives miR-��� overexpression and t�e resultant alteration of cellular processes� including cell cycle regulation� mitoc�ondria function� apoptosis� angiogenesis and metastasis [��] .
T�e migration of tumor cells is mediated by loss of E-cad�erin� w�ic� results in a more invasive p�e-notype� dissemination of t�e tumor cells by increased vascular permeability and survival in t�e bloodstream t�roug� resistance to apoptosis as well as ad�esion at t�e premetastatic nic�e� all of t�em being controlled by factors under t�e influence of HIF-� [�7].
HIF-�α in�ibits fatty acid β-oxidation �FAO� by in�ibiting two FAO enzymes� t�e medium-c�ain acyl-CoA de�ydrogenase ��CAD� and long-c�ain acyl-CoA de�ydrogenase �LCAD� t�at catalyze t�e first step of FAO in mitoc�ondria. Bot� �CAD-and LCAD-regulated FAO facilitates tumor cell proliferation by altering ROS levels and glycolysis. However� deficiency of LCAD-induced unsaturated fatty acid oxidation affects largely cancer progression by regulating t�e PTEN pat�way [��] and enabling rapid growt� and division of cancer cells.
Recently� Krtolica et al.
[��] assayed t�e efficacy of O�X-4.��P �long-acting oxygen carrier in circulation and tumor� t�at downregulates HIF-� pat�way in intracranial glioblastoma models in nude mice� Experimental Oncology ��� ����� ���� ��arc�� ��� ����� ���� ��arc�� ��arc�� �� immunocompetent rats and in spontaneous canine brain tumors. T�e preclinical data demonstrate t�at �ypoxia reduction and HIF-� pat�way downregulation dramatically en�ance response to radiation t�erapy leading to tumor cures. In t�e recent study� ��% of examined ��� invasive breast cancers from an African population s�owed strong HIF-�α expression� w�ic� was significantly associated wit� ot�er factors of poor prognosis like VEGF expression and increased angiogenesis� �ig� tumor cell proliferation by Ki-�7 rate� p5� expression� as well as �ig� �istological tumor grade [��] . Nuclear expression of HIF-�α was found in �7% cases of endometrial cancer patients. Hig�er HIF-�α expression was associated wit� �ig�er risk of recurrence [��] . Immuno�istoc�emical studies demonstrated t�at 4�% of examined primary pancreatic cancers were HIF-�α positive and t�e status of HIF-�α was significantly correlated wit� metastatic status� VEGF expression and intratumoral microvessel density [��] . Overexpression of HIF-�α was found to be an indicator of poor prognosis for patients wit� gastric cancer and was significantly correlated wit� �istology� dept� of invasion� VEGF� and microvessel density [��� �4].
HIF-�α overexpression was more frequent in patients wit� �epatic metastases in peritoneal cavity. T�e patients wit� HIF-�α overexpression �ad a s�orter disease-free survival and overall survival t�an patients wit� weak expression [�5]. Hig� HIF-�α expression is associated wit� t�e development and progression of �epatocellular carcinoma [��] . Oxygen-regulated component of HIF-� �HIF-�α� is overexpressed in clusters of leukemic cells in t�e bone marrow specimens of c�ild�ood acute lymp�oblastic leukemia �ALL� and absent in biopsies of normal bone marrow [�7]. Half of HIF-�α-positive ALL biopsies ex�ibited VEGF coexpression. In all ALL specimens� HIF-�α immunostaining was concentrated primarily wit�in t�e nuclei of leukemic cells.
Considering t�e multiple roles of HIF-� in tumor progression and metastasis� t�ere �as been great interest in developing in�ibitors targeting t�is pat�way. �ost of t�e reported HIF-�α in�ibitors were originally discovered for targeting ot�er endogenous molecules and later t�eir HIF-�α in�ibitory activity was recognized t�roug� some empirical testing [��] . In particular� cardiac glycosides were identified as in�ibitors of HIF-�α. Digoxin decreases cell proliferation and viability in liver cancer cell line [��] .
Cisplatin downregulates t�e level of t�e regulatable α subunit of HIF-�� HIF-�α� in cisplatin-sensitive ovarian cancer cells t�roug� en�ancing HIF-�α degradation but does not downregulate HIF-�α in t�eir cisplatin-resistant counterparts [��] . P�armacological promotion of HIF-�α degradation en�ances response to cisplatin in bot� cisplatin-sensitive and cisplatinresistant ovarian cancer cells. T�ese findings suggest t�at t�e HIF-�α-regulated cancer metabolism pat�way could be a novel target for overcoming cisplatin resistance in ovarian cancer. . In NAPOLI-�� global� randomized P�ase III study evaluating nal-IRI -a nanoliposomal irinotecan -wit� or wit�-out fluorouracil and leucovorin in 4�7 patients wit� metastatic pancreatic cancer previously treated wit� gemcitabine-based t�erapy� overall survival benefit for nal-IRI plus fluorouracil and leucovorin over fluorouracil and leucovorin wit� a similar safety profile �as been demonstrated [�5] . Combination c�emot�erapy wit� oral S-� and biweekly �4-�our infusions of irinotecan plus bevacizumab appears to be �ig�ly active and well tolerated bot� as first-line and second-line c�emot�erapy for metastatic colorectal cancer [��] . In�ibition of HIF-�α by PX-47� en�ances t�e antitumor effect of gemcitabine by inducing immunogenic cell deat� in pancreatic ductal adenocarcinoma [�7] .
In summary� blocking �ypoxia and HIF-� pat�way is beneficial in targeting solid cancers. Nevert�eless� t�ere �ave been several approved drugs t�at affect t�e HIF-�α pat�way and could serve as adjuvant t�erapy for certain types of cancers along wit� t�e existing treatments. Future developments would be directed towards t�e drugs t�at are more specific for HIF-� in�ibition [��] .
